Asset Management One Co. Ltd. Cuts Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Asset Management One Co. Ltd. cut its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 6.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 428,837 shares of the company's stock after selling 28,534 shares during the period. Asset Management One Co. Ltd.'s holdings in Teva Pharmaceutical Industries were worth $6,591,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TEVA. GHP Investment Advisors Inc. raised its stake in Teva Pharmaceutical Industries by 58.7% during the 1st quarter. GHP Investment Advisors Inc. now owns 50,884 shares of the company's stock valued at $782,000 after buying an additional 18,819 shares during the last quarter. Whalen Wealth Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $404,000. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 97.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 84,263 shares of the company's stock worth $1,295,000 after acquiring an additional 41,600 shares during the period. Retirement Systems of Alabama purchased a new stake in Teva Pharmaceutical Industries during the first quarter valued at $6,167,000. Finally, Essex Savings Bank lifted its holdings in Teva Pharmaceutical Industries by 13.5% in the first quarter. Essex Savings Bank now owns 16,770 shares of the company's stock valued at $258,000 after acquiring an additional 2,000 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $0.38 during trading on Wednesday, reaching $17.02. The company's stock had a trading volume of 8,343,532 shares, compared to its average volume of 10,241,326. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. The company has a market capitalization of $19.52 billion, a P/E ratio of -14.80, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60. The company's fifty day moving average is $16.84 and its 200-day moving average is $17.40.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.48 earnings per share. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the topic of several recent research reports. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Buy" and an average price target of $24.13.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president owned 9,989 shares in the company, valued at $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.55% of the stock is currently owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.